fashion -WSS

fashion

author：explore 2025-10-02 10:38:47 - browse：36

A caretaker speaks with an elderly Alzheimer's patient at a nursing home. — ALAIN JOCARD/AFP via Getty Images

For more than 30 years, Alzheimer’s researchers have thought of APOE4 as a major genetic risk factor for most cases of the devastating neurologic disease. But a new study published on Monday argues that this gene variant plays an even more important role than scientists had realized and causes a distinct form of Alzheimer’s.

Researchers analyzed data from more than 13,000 people, including nearly 800 APOE4 homozygotes, people who carry two copies of the gene variant. They found that nearly all of the homozygotes showed biological signs of Alzheimer’s in the brain, and they typically developed dementia and other symptoms, and died sooner, than people with Alzheimer’s who lack APOE4.

The research team also found that APOE4 homozygotes showed a predictable pattern of biomarker changes linked to Alzheimer’s, including a buildup of beta-amyloid and tau, a protein linked to neuron damage and death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： A common UTI test for kids haunts adults as a traumatic 'nightmare'

entertainment

WSS

How housing is health care on Long Island

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

New weight loss drugs vying to be the next Wegovy or Mounjaro

Hospitals consider fixing cancer drug shortages on their own

World's first CRISPR

Weight loss drug costs may need more research, senator suggests

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

How medical schools plan to diversify without affirmative action

Psychedelics group wrestles with new pharma identity

Private equity could exacerbate cardiology's overuse problem, experts fear

ChatGPT in medicine: STAT answers readers' burning questions

New Covid vaccine is recommended for everyone 6 months or older

Wildfire smoke exposes gaps in outdoor worker protections

Hospitals look to new technology to keep health care workers safe

Trump demands the U.S. pay no more for drugs than other countries … again

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

focus

FDA panel endorses Alnylam’s heart drug — after picking it apart

FDA's Woodcock to retire early next year

Weight loss drug costs may need more research, senator suggests

Regeneron agrees to White House price limits on anti

Poor hospice wound care hurts patients and families

Popular nasal decongestant doesn't actually relieve congestion

entertainment

entertainment

focus

leisure time